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Abstract
Prostate cancer (PCa) is the second leading cause of mortality in men, the present diagnosis method being 
based on serum prostate-specific antigen (PSA) screening, with low specificity and overestimated values. A 
combined untargeted and targeted metabolomic study of metabolites from blood serum samples collected from 
healthy (n=11), hyperplasia (n=39) and  prostate cancer (n=83) patients is presented, using the HPLC–(ESI+) 
QTOF-MS analysis. The profile of blood serum samples provided complementary information obtained from Base 
Peak Chromatograms and Dissect chromatograms. Based on dissect chromatograms, two different methods of 
statistical analysis were used, either based on the instrument software with automated alignments with/without 
normalization (Profile Analysis), or based on manual alignment followed by statistical analysis (Unscrambler10.X 
software). Both methods used the unsupervised Principal Component Analysis which discriminated between 
normal, hyperplasia and cancer patients. The second method allowed a better discrimination between groups, 
by qualitative and quantitative parameters (m/z values versus peak areas) and better possibilities to identify the 
molecules responsible for such discriminations. 
Considering the retention time interval (6-17 min), four molecules to be considered as putative biomarkers 
for hyperplasia or prostate cancer were identified: Prostaglandins E2/G2, Pregnenolone/ethyltestosterone, 
Lysophosphatidylcholine18:2/0:0, Galactosylceramide (18:1/24:1). 
By using larger patient cohorts and optimizing the data processing and chemometric analysis, more reliable 
biomarkers for prostate hyperplasia and cancer can be discovered and quantified. This preliminary study has had 
promising findings for the implementation and validation of metabolomic targeted analysis in clinical laboratories.
Keywords: untargeted/targeted metabolomics, prostate cancer, biomarkers, small metabolites, LC-MS
INTRODUCTION
Prostate cancer (PCa) is the second leading 
cause of cancer-related mortality in men (Cancer 
Facts & Figures 2013; Landis et al., 1998). The 
common diagnosis method is based on the serum 
prostate-specific antigen (PSA), digital rectal 
examination and ultrasound-guided prostate 
biopsy screening test.
Metabolome is a data-rich source of informa-
tion concerning all the low-molecular-weight 
metabolites in a tissue, cell or biofluid, which 
can indicate biochemical changes in different 
pathways and possible perturbations in pathologic 
situations. The emerging field of metabolomics, 
in which a large number of small-molecule 
metabolites from body fluids or tissues are detec-
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ted qualitatively or quantitatively, in a single 
step, promises great potential for early diagnosis, 
for therapy monitoring and for understanding 
the pathogenesis of many diseases (Park et 
al., 2012). Metabolic biomarkers are useful for 
routine screening of inborn errors of metabolism 
using either chromatography coupled with mass 
spectrometry or tandem mass spectrometry 
(Chace et al., 2002; Piraud et al., 2003).
However, global metabolite profiling of 
prostate cancer patients still remains in an early 
stage, and there is no biomarker panel currently in 
use for clinical testing (Trock, 2011).
Tissue sarcosine levels were proposed 
some years ago as a potential biomarker for the 
aggressive form of the disease in a metabolomic 
profiling study using both liquid- and gas-
chromatography coupled to mass spectrometry 
(LC-MS and GC-MS). Its concentration in prostate-
cancer related tissue specimens was highly 
increased during PCa progression to metastasis, 
but differences in urine were much less marked 
(Sreekumar et al.,   2009). The controversial blood 
serum sarcosine does not discriminate between 
the three groups of men (control, localized prostate cancer and metastasized castration-resistant 
prostate cancer). Moreover, on an individual basis 
the sarcosine concentration was not relevant with 
respect to increased PSA concentrations and to 
prostate cancer progression. Serum sarcosine 
data in conjunction with the urinary sarcosine 
data (Sreekumar et al.,  2009) shows that there are no major alterations in the extracellular 
concentrations of sarcosine, the assessment 
of sarcosine having a limited potential in the 
diagnostic algorithm of prostate cancer (Stuys et 
al.,   2010).
 The analysis of cancerous tissues by proton 
high-resolution magic-angle spinning nuclear 
magnetic resonance (NMR) spectroscopy has 
shown a decrease in the concentrations of 
citrate and polyamines and increases in choline, 
glycerophospholipids and lactate concentrations 
during prostate cancer proliferation (Swanson et 
al., 2003, 2006). Increased levels of cholesterol, 
as well as alterations in amino acid metabolism 
were detected in metastatic bone samples by GC-
MS (Thysell et al., 2010). However, none of these 
studies included enough patients to offer strong 
leads on the metabolic alterations associated with prostate cancer. 
Other metabolomic studies focused on the 
identification of relevant blood biomarkers for 
early diagnosis of prostate cancer. Zhou (2012) 
identified the lipid profile of 141 plasma lipids 
of patients with prostate cancer and 36 samples 
from healthy patients. The most significant 
lipid species as a biomarker candidate was 
lysophosphatidilcholine 22:6 (p=0.144). Higher 
concentrations of cholesteryl ester species with 
linoleic acid and phosphatidylcholine PC(34:2) 
were noticed. Other studies (Keshari, 2011; 
Zhou, 2011; Zaidi, 2013) identified significant 
modifications of phosphatidylethanolamine (PE), 
ether-phosphatidylethanolamine (ePE) and ether-
phosphatidilcholine (ePC). Studies on larger 
cohorts are needed. More robust and reproducible 
metabolic models still need to be developed for 
improved understanding of disease progression 
and more reliable prostate cancer detection.
This paper reports an untargeted metabolomic 
procedure based LC-QTOF-(ESI+)-MS technique 
applied for polar molecules from blood serum of 
prostate cancer patients (histologically classified) 
compared with healthy controls. By multivariate 
analysis (Principal Component Analysis and 
Cluster Analysis), the discriminations between 
groups have been proved and possible biomarker 
candidates for diagnosis have been identified.
MATERIALS AND METHODS
Blood sample collection
The blood samples were collected from 37 
prostate cancer patients before surgery (CO 
group) (mean age 62.9±5.7years), 46 prostate 
cancer patients before biopsy (CB group) (mean 
age 66.7±7.6), 39 benign prostatic hyperplasia 
patients (H group) (mean age 63.8±7.7), and 11 
healthy individuals (M group) (mean age 27±5.2). 
After securing the patients’ agreement on the 
protocol, blood samples were collected at Municipal 
Clinic Hospital Cluj-Napoca by venipuncture into 
vacutainer tubes without anticoagulant. Serum 
was obtained by centrifugation at 2000 rpm 
for 10 minutes and aliquots of 1 ml were frozen 
and stored at −20 °C for further use. The sample 
collection and storage procedures for prostate 
cancer patients and healthy individuals were 
identical. Histologic classification was obtained 
meanwhile and quantified by Gleason scores, as 
well the PSA values, for each patient.
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For the metabolomic analysis, a stock sample 
of human blood serum was used to develop the 
serum sample preparation protocol and HPLC–
(ESI+)QTOF-MS method. Serum samples were 
thawed on ice, and protein precipitation was 
performed by the addition of methanol to a volume 
of 200 μL serum in a 5:1 volume ratio. Samples 
were vortexed for 20s, sonicated for 5 minutes 
and centrifuged at 1500g for 15 minutes. The 
supernatant was collected, filtered through 0.2 µm 
filters and kept in the deep freezer until analysis.
HPLC–ESI(+)-QTOF-MS analysis 
Aliquots of 5 µl serum were subjected to 
chromatography on a Thermo Scientific HPLC 
UltiMate 3000 system equipped with a quaternary 
pump system DionexUltiMate 3000 (UHPLC), a 
DionexUltimate 3000 photodiode array detector, column oven and autosampler.
Serum metabolites were separated using a 
Thermo Scientific Acclaim C-18 column (3µm, 2.1 
X 50 mm) at 40°C. The mobile phase consisted of 
0.1% formic acid in water (A) and 0.1% formic 
acid in acetonitrile (B). The flow rate was set at 0.5 
mL·min−1. The gradient elution initial conditions 
were 1% B with linear gradient to 15% B from 0 
to 3 min, followed by linear gradient to 50% B at 
6 min, linear gradient to 95% B at 9 min, isocratic 
on 95% B for 6 min and then returned to initial 
conditions at 15 min and kept isocratic at 1% B 
for 5 min. The PDA detector was set at 270 nm. 
The eluent was introduced directly into the mass 
spectrometer by electrospray.
 The mass spectrometry was performed on a 
BrukerDaltonicsMaXis Impact QTOF instrument, 
operating in positive ion mode (ESI+). The 
mass range was set between 50-1000 m/z. The 
nebulizing gas pressure was set at 2 bar, the drying 
gas flow at 8 L/min, the drying gas temperature 
at 180 ºC. Before each chromatographic run, a 
calibrant solution of sodium formate was injected. 
The control of the instrument and data processing 
were done using TofControl 3.2 and Data Analysis 
4.1 (BrukerDaltonics).
Statistical Analysis
The unsupervised analysis was done by 
Principal Component Analysis (PCA) method to 
discriminate between normal and pathologic 
samples,  using the instrument algorithm and 
Profile Analysis software (Bruker, Daltonics) 
(statistical method 1), as well as manual alignment 
of retention times and PCA analysis by the 
Unscrambler 10X.1 (statistical method 2). 
Statistical method 1 included the alignment 
parameters, with or without normalization, in 
the whole separation interval, from min 1 to 17. 
The limits of bucket filter were either >50% 
(considering the profiles which are common for 
at least 50% of molecules) or > 90% (considering 
the profiles which are common for at least 90% 
of molecules). The S/N thresholds were 5.0 for 
chromatograms and 1.0 for MS peak finders. The 
coefficient of correlation was established to be 0.7 
without smoothing and the search range m/z was 
0.5. Statistical method 2 included the manual 
alignment of the m/z values in the separation 
interval, from min 6 to 17. Such alignment was 
necessary since the same molecules had shifted 
values of RT, of about 0.1-0.3 min.
The PCA scores plots (by both methods) 
indicated the spectral similarity between samples 
and allowed the classification of normal or 
pathological samples. The loadings were based 
either on m/z values (to identify qualitative 
differences between samples) or peak areas (to 
identify semi-quantitative differences). The PCA 
analysis was used also to verify the metabolite 
homogeneity of each group (based on retention 
times, peak areas and m/z values).
RESULTS AND DISCUSSION
1. Untargeted fingerprint of blood serum 
by HPLC–(ESI+)QTOF-MS analysis
The metabolomic serum profile by HPLC–
(ESI+)QTOF-MS analysis is a rapid and sensitive 
method which acquires robust results and allows 
the simultaneous identification of known and 
unknown compounds.
Fig. 1 (A- D) shows the different patterns of 
base peak chromatograms (BPC) of serum samples 
from patients with benign prostatic hyperplasia 
(H), CB, CO groups, compared with controls (M).
There were 7-9 main peaks separated and 
identified in BPC chromatograms of the four 
groups H, CB, CO and M. Such peaks represent the 
major components, representing especially the phospholipids.
A more detailed composition is offered by 
the Dissect chromatograms, processed by the 
instrument Data analysis software, as shown in 
Fig.2 (A-D) for the same groups of patients.
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Dissect chromatograms contain 68-85 peaks 
showing a large diversity of major and minor 
molecules. For each molecule, the m/z and peak 
area values were recorded. 
2. Statistical analysis (method 1)
To perform an adequate interpretation of 
untargeted data, the unsupervised PCA method was 
applied, the alignments being made automatically 
by Profile Analysis software attached to Bruker 
Data Analysis which built specific bucket matrices. 
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Fig. 1. Base peak chromatograms recorded for serum samples from the four groups of 
patients: H (A), CB (B), CO(C) and M(D).  
A. B.
C. D.
Fig. 2. Dissect chromatograms recorded for serum samples from the four groups of patients: 
H (A), CB (B), CO(C) and M(D).  
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Different parameters were applied to compare 
the principal components with the best variance 
percentages, to discriminate groups M-CB, M-H, 
M-CO, H-CB, H-CO, in the whole separation interval, 
from minute 1 to 17, as mentioned in Materials 
and Methods.
Fig.3 A-D represents the scores and loadings 
plots which compare the M group (triangle) with CB 
(circles) group of patients, without normalization 
(A) or with normalization, considering the largest 
bucket values (B and D) or the sum of bucket 
values (C) .
The patterns of these plots indicate differences 
between the non-normalized and normalized data, 
diagrams B and D were similar, while diagram 
C, which considered the sum of bucket values, 
discriminated groups M and CB more significantly.
3. Statistical analysis (method 2)
By manual alignment, the common m/z 
values were considered as found in each group 
between RT=6-17 min. minute 6 to 17, eliminating 
the interval 1 - 6 min, where insignificant, minor 
molecules were separated. 
From the m/z values obtained, it was possible 
to establish the homogeneity of each group and 
that between groups, based on the relation RT-
area and RT-m/z using Principal Component 
Analysis realized with Bruker-Profile Analysis and 
Unscrambler 10x software.
Fig.4 shows the results of PCA analysis 
(scores and loadings plots) made by Unscrambler 
software, after the manual alignment of molecules, 
considering the RT range from 6 to 17 min. Such 
analysis took into account the relation RT- Peak 
area (up) or RT-m/z values (down) for the four 
groups of patients (M, H, CB, CO). While the RT- 
Peak area relationship (Fig.4. up) represents a 
quantitative discrimination, the RT-m/z values 
(down) identify the specific molecules which 
discriminate the groups qualitatively.
In the score plots of RT-peak area correlations 
which are important for quantitative evaluation, 
one can see that RT values of 9.8, 10.1, 11.6, 12.6-
12.7, 14.7, 16.8 min can explain the discrimination 
among groups. Loadings plots show a good 
separation of M group, but they do not indicate 
good discrimination between H, CB and CO groups.
In the score plots of RT-m/z correlations 
which are important for qualitative evaluation, 
one can see that compounds having RT values 
of 9.8, 10.1, 12.3-12.8, 14.8, 16.7 and 17 min can 
explain the discrimination among groups. In this 
case, loadings plots show a better separation (in positive versus negative axis) of M group, but they 
do not indicate good discrimination between H, 
CB and CO groups.
Finally, we can conclude that similar RTs 
explain qualitative and quantitative differences 
between the groups M-H-CB-CO, and that the 
manual alignment gave superior information of 
biological significance.  
A. B.
C. D.
Fig. 3. Profile analysis of untargeted data with alignments, comparing the M (triangle) and 
CB (circles) groups, without normalization (A)  or with normalization, considering the 
largest bucket values (B and D) or the sum of bucket values (C) . The whole 1-17 RT interval 
was considered.
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4. Targeted metabolomic analysis for 
different RT intervals
Based on the untargeted analysis and 
PCA statistics (methods 1 and 2), the targeted 
metabolomic analysis took into consideration the 
most significant retention times, mentioned above: 
RT= 8.1-8.2 min corresponding to pregnenolone/
ethyltestosterone with m/z= 317.13 (prostate-
related hormone), RT= 11.6-11.9 min for 
prostaglandins PGE2/G2 with m/z=353.26, 
RT=9.8 min corresponding to LPC (18:2/0:0), m/
z=520.34 and RT=14.1-14.3 min corresponding to GlcCer (d18:1/18:0), m/z=728.59. For these 
targeted molecules, the mean peak area values 
and standard deviation were calculated and 
represented (data not shown). The identification 
was made using Human Metabolome Database 
(www.hmdb.ca) and Lipidomics Gateway (www.
lipidmaps.org). Other RT values of 11.0, 12.4-
12.5, 13.8-14.0 and 14.2 were considered, where 
diacylglicerols and monoacylglycerols were 
identified.
Increases of prostaglandins peak areas were 
gradually noticed, from M group to CO group 
suggesting that PGE2/PGD2 may represent good 
biomarkers for prostate cancer.  Nevertheless, 
these data need validation, since standard devia-
tions were high. Considering the RT= 8.1-8.2 min 
peak areas, corresponding to pregnenolone/
ethyltestosterone, a slight decrease from M to 
H/CO/CB groups was observed, while for LPC 
(18:2/0:0) gradual increases from M to H and 
CO/CB groups were noticed. Concerning the 
Galactosylceramide (d18:1/18:0), peaks separated 
at RT=14.1-14.3 min, the highest increases were 
noticed for H group against controls (M) and slight 
increases in CO/CB groups. One can suggest that 
Galactosylceramide may represent a putative 
biomarker for Hyperplasia. In addition to these 
data, we noticed modifications in the peak areas 
corresponding to some free fatty acids (linoleic, 
stearic), amino acids and nucleosides.
Our results are in good agreement 
with literature data which show that blood 
prostaglandins increase in prostate cancer, PGE2 
being highly expressed in the prostate, associated 
with prostate cancer progression (Jain, 2008; 
Terada, 2014). Such bioactive lipids are potent 
mediators of several signal transduction pathways 
that modulate cellular adhesion, growth and 
differentiation (Badawi, 2000). Previous findings 
have also shown abnormalities in fatty acids 
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Fig.4. PCA analysis (scores and loadings) determined after the manual alignment of molecules, at RT 
range from 6 to 17 min. Such analysis took into account the relation RT- Peak area (up) or RT-m/z 
values (down) for the four groups of patients (M, H, CB, CO).
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(Liu, 2006), and amino acids (Sreekumar et al., 
2009; Ebenezar et al.,   2012; Fu et al., 2010) 
metabolism in prostate cancer  patients. Such data 
have been confirmed recently by our results as 
well (Romanciuc et al, unpublished data). Overall, 
patients with prostate cancer (CO and CB groups) had increased serum polar lipid concentrations 
(excepting phosphatidic acid, a precursor 
significantly lower in patients with prostate 
cancer). This imbalance in plasma concentrations 
among lipid classes could be caused by increased 
synthesis of phospholipids in prostate cancer cells 
resulting in over-consumption of the precursor 
(Athenstaedt and Daum, 1999). In general, 
lysophospholipids can bind and activate specific 
cell-surface G protein-coupled receptors (GPCRs) 
that initiate cell growth, proliferation and survival 
pathways, and show altered concentrations in 
cancer cells, and thus in combination with other 
specific markers have the potential to contribute 
to early diagnosis (Murph et al., 2007). Among 
the different lysophospholipids identified that 
may play a role in cell signalling, lysoPC(18:2) and 
lysoPC(18:0) have been reported as biomarkers 
for prostate cancer detection within a panel of 
plasma lipids (Peyruchaud, 2009; Zhou et al., 
2012). Ceramides, belonging to sphingolipid class, 
act as second messengers in apoptosis induction in 
many cells, including prostate cancer cells, being 
identified as potential chemotherapeutic agents for 
prostate cancer. Hormones such as androgens are 
crucial for the normal development of the prostate 
gland and in maintaining its functional state in the 
adult. The prolonged presence of androgens may 
be a risk factor in the development of prostate 
cancer (Armstrong, 1982; Wilding, 1995). 
Pregnenolone and ethyltestosterone derivatives 
are included in the steroid hormone pathway 
which supplies androgens, such as testosterone 
and 5α-dihydrotestosterone, which stimulate 
the androgen-dependent prostate cancer cells 
proliferation, as shown by many authors (Kliman 
et al., 1978; Zumoff et al., 1982; Castagnetta and 
Carruba, 1995; Signorello et al.,   1997; Titus et 
al.,   2005; Knudsen and Scher, 2009; Zang et al., 
2014).
CONCLUSION
The results of this preliminary study show that 
the untargeted metabolomic analysis, using the 
chromatographic fingerprint HPLC–(ESI+)QTOF-
MS and profile of blood serum samples offered 
complementary information, obtained either 
from Base Peak Chromatograms or from Dissect 
chromatograms. Based on dissect chromatograms, 
two different methods of statistical analysis were 
used: one based on the instrument software 
with automated alignments with/without 
normalization (Profile Analysis), and another one 
based on manual alignment followed by statistical 
analysis using the specialized Unscrambler 
software.  Both methods used the unsupervised Principal 
Component Analysis (PCA) to discriminate 
between normal, hyperplasia and cancer patients, 
establishing meanwhile the homogeneity of 
each sample group and the clustering of groups. 
Comparing these two methods, we conclude that 
the second method allowed a better discrimination 
between groups, by both qualitative and 
quantitative parameters (m/z values versus peak 
areas), and better possibilities to identify the 
molecules responsible for such discriminations. 
Considering the retention time interval from 
6 to 17 minutes, by targeted metabolomic analysis 
four molecules were identified which can be 
considered good candidates as putative biomarkers 
for hyperplasia or prostate cancer: Prostaglandins 
PGE2/G2, Pregnenolone/ ethyltestosterone, 
lysophosphatidylcholine18:2/0:0 and 
Galactosylceramide (18:1/24:1). Also, other 
molecular types were identified (e.g. fatty acids, 
aminoacids, nucleosides,etc) which will be 
presented in future studies.
Finally, we consider that using larger patient 
cohorts and optimizing the data processing and 
chemometric analysis, more reliable biomarkers 
for prostate hyperplasia and cancer can be 
discovered and quantified. This preliminary study 
showed good promise towards the implementation 
and validation of metabolomic targeted analysis in 
clinical laboratories.
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